Tinea Pedis Treatment Market - Drug Class, Disease Type, Route of Administration, Type, Age Group, Distribution Channel, Global Forecast

Description

Global Tinea Pedis Treatment Market will register 4.3% CAGR between 2024 and 2032, owing to rapid advancements in treatment methods and increased R&D investments. Innovative therapies, such as microneedle patches, are providing effective and convenient alternatives to traditional antifungal medications for enhancing patient outcomes.

Increased R&D investments are also fuelling the discovery of novel drug delivery systems and more potent treatments for addressing the rising incidence of fungal infections. These advancements are improving treatment efficacy, patient compliance, and market accessibility, further contributing to the market expansion. For instance, in July 2023, a research team headed by Kelvin Yeung from the Department of Orthopaedics and Traumatology at the School of Clinical Medicine, LKS Faculty of Medicine, University of Hong Kong HKUMed developed a new microneedle patch for offering an effective non-antibiotic treatment for skin infections, including tinea pedis.

The industry is segmented into drug class, disease type, route of administration, type, age group, distribution channel, and region.

By route of administration, the tinea pedis treatment market from the prescription segment will witness remarkable expansion through 2032 due to the efficacy and reliability of prescription medications. These treatments often contain higher concentrations of active ingredients compared to over-the-counter OTC options for providing more effective and faster relief from symptoms. Healthcare professionals also frequently recommend prescription treatments for persistent or severe cases.

Based on distribution channel, the tinea pedis treatment industry from the retail pharmacies segment will garner considerable gains by 2032, attributed to their widespread accessibility and convenience for consumers seeking OTC and prescription medications. Retail pharmacies provide a variety of treatment options, from topical creams to oral antifungals, making it easy for patients to obtain necessary treatments. As healthcare awareness and the demand for effective treatments is growing, the preference for retail pharmacies will further rise.

Asia Pacific tinea pedis treatment market will witness a noteworthy CAGR from 2024 to 2032, propelled by the rapidly growing population, increasing incidence of fungal infections, and rising awareness about foot hygiene. The expanding healthcare infrastructure and higher disposable incomes of the region are enabling greater access to both OTC and prescription treatments. Additionally, the presence of major market players and ongoing advancements in treatment options will contribute to the regional industry growth.

Product Code: 9143

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of tinea pedis
  - 3.2.1.2 Availability of effective OTC drugs
  - 3.2.1.3 Growing awareness about tinea pedis and its symptoms
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Increased resistance to antifungal medications
  - 3.2.2.2 Availability of alternative treatment options
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Antifungals
5.3 Combination drugs

Chapter 6 Market Estimates and Forecast, By Disease Type, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Interdigital tinea pedis
6.3 Plantar tinea pedis
6.4 Vesicular tinea pedis
6.5 Acute ulcerative tinea pedis

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

7.1 Key trends
- 7.1.1 Topical
- 7.1.2 Cream
- 7.1.3 Gel
- 7.1.4 Lotion
- 7.1.5 Powder
- 7.1.6 Spray
- 7.1.2 Oral

Chapter 8 Market Estimates and Forecast, By Type 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 OTC drugs
8.3 Prescription drugs

Chapter 9 Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 Below 18 years
9.3 19 - 35 years
9.4 36 - 50 years
9.5 51 years and above

Chapter 10 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

10.1 Key trends
10.2 Hospital pharmacies
10.3 Retail pharmacies
10.4 Online pharmacies

Chapter 11 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

11.1 Key trends
11.2 North America
- 11.2.1 U.S.
- 11.2.2 Canada
11.3 Europe
- 11.3.1 Germany
- 11.3.2 UK
- 11.3.3 France
- 11.3.4 Spain
- 11.3.5 Italy
- 11.3.6 Netherlands
- 11.3.7 Rest of Europe
11.4 Asia Pacific
- 11.4.1 China
- 11.4.2 Japan
- 11.4.3 India
- 11.4.4 Australia
- 11.4.5 South Korea
- 11.4.6 Rest of Asia Pacific
11.5 Latin America
- 11.5.1 Brazil
- 11.5.2 Mexico
- 11.5.3 Rest of Latin America
11.6 Middle East and Africa
- 11.6.1 South Africa
- 11.6.2 Saudi Arabia
- 11.6.3 UAE
- 11.6.4 Rest of Middle East and Africa

Chapter 12 Company Profiles

12.1 Bausch Health Companies Inc.
12.2 Bayer AG
12.3 GlaxoSmithKline plc
12.4 Glenmark Pharmaceuticals Limited
12.5 Pfizer, Inc.
12.6 Sebela Pharmaceuticals Holdings Inc.
12.7 Smith & Nephew plc
12.8 Sun Pharmaceutical Industries Ltd
12.9 Teva Pharmaceutical Industries Limited
12.10 Viatris Inc.